0001643405-15-000001.txt : 20150528 0001643405-15-000001.hdr.sgml : 20150528 20150527173810 ACCESSION NUMBER: 0001643405-15-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20150528 DATE AS OF CHANGE: 20150527 EFFECTIVENESS DATE: 20150528 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Calimmune, Inc. CENTRAL INDEX KEY: 0001643405 IRS NUMBER: 113763470 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-240650 FILM NUMBER: 15893332 BUSINESS ADDRESS: STREET 1: 5151 E. BROADWAY BLVD., SUITE 1020 CITY: TUCSON STATE: AZ ZIP: 85711 BUSINESS PHONE: 310-806-6240 MAIL ADDRESS: STREET 1: 5151 E. BROADWAY BLVD., SUITE 1020 CITY: TUCSON STATE: AZ ZIP: 85711 D 1 primary_doc.xml X0707 D LIVE 0001643405 Calimmune, Inc. 5151 E. BROADWAY BLVD., SUITE 1020 TUCSON AZ ARIZONA 85711 310-806-6240 DELAWARE None None Corporation true Louis Breton c/o Calimmune, Inc. 5151 E. Broadway Blvd., Suite 1020 Tucson AZ ARIZONA 85711 Executive Officer Director David Baltimore, Ph.D. c/o Calimmune, Inc. 5151 E. Broadway Blvd., Suite 1020 Tucson AZ ARIZONA 85711 Director Peter Kolchinsky c/o RA Capital Healthcare Fund, LP 20 Park Plaza, Suite 1200 Boston MA MASSACHUSETTS 02116 Director Harry A. George c/o Calimmune, Inc. 5151 E. Broadway Blvd., Suite 1020 Tucson AZ ARIZONA 85711 Director Jon Faiz Kayyem, Ph.D. c/o Calimmune, Inc. 5151 E. Broadway Blvd., Suite 1020 Tucson AZ ARIZONA 85711 Director David H. Donabedian, Ph.D. c/o AbbVie UK Pharmaceuticals Ltd. Abbott House,Vanwall Bus Park,VanwallRd Maidenhead, Berkshire X0 UNITED KINGDOM SL6 4XE Director Bhavin Raval c/o Calimmune, Inc. 5151 E. Broadway Blvd., Suite 1020 Tucson AZ ARIZONA 85711 Executive Officer Biotechnology Decline to Disclose 06b false 2015-05-12 false true true true true Securities offered consist of Series B Pref Stock, Warrants exercisable for shares of Common and Series B Pref Stock, the Common and Series B Pref Stock issuable upon exercise of the Warrants and the common stock underlying the Series B Pref Stock. false 0 15988448 15851969 136479 The amount listed above includes the amount receivable upon the exercise of warrants to purchase shares of Common and Series B Preferred Stock. Such warrants have not yet been exercised. false 51 0 0 0 false Calimmune, Inc. Louis Breton Louis Breton President and Chief Executive Officer 2015-05-26